Genoptix (Genoptix) Total Stockholders Equity : $208.69 Mil (As of Sep. 2010)

View and export this data going back to . Start your Free Trial

What is Genoptix Total Stockholders Equity?

Genoptix's Total Stockholders Equity for the quarter that ended in Sep. 2010 was $208.69 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Genoptix's Book Value per Share for the quarter that ended in Sep. 2010 was $N/A. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Genoptix's Debt-to-Equity for the quarter that ended in Sep. 2010 was 0.00.

Genoptix Total Stockholders Equity Historical Data

The historical data trend for Genoptix's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genoptix Total Stockholders Equity Chart

Genoptix Annual Data

Trend

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Total Stockholders Equity

Get a 7-Day Free Trial

7.52

4.07

90.61

132.22

179.50

Genoptix Quarterly Data
	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10
Total Stockholders Equity	Get a 7-Day Free Trial															167.77	179.50	190.01	201.04	208.69

Genoptix (DELISTED:GXDX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Genoptix's Book Value per Share for the quarter that ended in Sep. 2010 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(208.689	-	0)	/	0
	=	N/A

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Genoptix's Debt-to-Equity for the quarter that ended in Sep. 2010 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	208.689
	=	0.00

Genoptix Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Genoptix's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Genoptix (Genoptix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genoptix Inc (DELISTED:GXDX) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Genoptix, Inc. incorporated in Delaware in January 1999. It is a specialized laboratory service provider, which is focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists, or hem/oncs. Its group of hematopathologists utilizes diagnostic technologies to provide a differentiated, specialized and integrated assessment of a patient's condition, aiding hem/oncs in making vital decisions concerning the treatment of malignancies of the blood and bone marrow, and other forms of cancer. The company's key service offerings, COMPASS and CHART, are designed to meet the specific needs of community-based hem/oncs. Its COMPASS service offering includes the determination by its hempaths of the appropriate diagnostic tests to be conducted and the performance of these tests. It then evaluate, synthesize and summarize the results into an easy to read comprehensive report, and its hempaths are available to interpret these results jointly with the hem/onc, giving them the benefit of its expertise and analytical experience. The company's CHART service offering combines multiple COMPASS assessments and analyses of disease progression after intervening clinical action, providing the hem/onc with a valuable diagnostic tool to track both a patient's disease and response to the hem/onc's prescribed treatment regimen over time. The Company believes its sales and marketing approach distinguishes it from its competitors. Most of its sales representatives have a four-year Bachelor of Science or Arts degree, primarily in the biological sciences, and a three-to five-year history selling diagnostic services or niche pharmaceuticals directly to hem/oncs. As a specialized diagnostic service provider, it relies extensively on its quality of service to attract and retain community-based hem/oncs and other healthcare professionals as its customers. As a diagnostic service provider, the Company is required to hold certain federal, state and local licenses, certifications and permits to conduct its business.

Genoptix (Genoptix) Headlines

No Headlines